A little help from CEO Novo Nordisk, page-8

The CEO of Ozempic manufacturer, Jorgensen's statement "The GLP-1 drugs are not a cure-all, and patients will still need other treatments" lends credence to RMD's statement the GLDP-1 drugs will bring people with undiagnosed sleep apnea into the health care funnel for treatment, The market should be able to see through the scare mongering the obesity wonder drugs will decimate the sleep apnea market. Instead, the wonder drugs have the potential to increase sleep apnea awareness and patient numbers for RMD,
Investors should also note that a purchaser of the RMD machine (Existing RMD patients) are not going to throw away the machine. He is more likely to continue using it and use the SAAS software to monitor his sleep apnea condition. This together with the Quarterly results validate RMD's statement of the high adherence rate of sleep apnea patiemts who are on GDLP1 drugs.